NASDAQ:STML
Delisted

Stemline Therapeutics Stock Signals

etoro logo Buy STML
*Your capital is at risk
$11.83
+0 (+0%)
At Close: Sep 04, 2020

Latest Data & Signals Issued

Below are some of the latest signals issued for Stemline Therapeutics

General

Signal Type Signal Value Data
Score 0.000 38 days ( 0 %
Last Price $11.83 0 %
Performance History
7 Days
$11.83 $11.83
0%
30 Days
$11.83 $11.83
0%
12 Mos
$11.27 $11.83
4.97%

6/18

Active Buy Signals

Specific Signals

Short Term
Net score: 15.54
Signal Type Signal Value Importance Data
High / Low N/A Very Low $11.83 - $11.83
Trend - 3 mos -0.190 % High Width: 1.44 %
Pred. range - 3 mos $11.79 - $11.95 Low -0.376 % - 1.05 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Jun 09, 2020 - 63 days
RSI Short Pivot Signal Buy Very Low Jun 25, 2020 - 51 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Jun 19, 2020 - 55 days
Short/Long MA 3 mos Sell Medium Jun 19, 2020 - 55 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 59.84
Signal Type Signal Value Importance Data
Trend - 12 mos 14.56 % Very High Width: 253.84 %
Pred. range - 12 mos $4.95 - $17.53 High -58.12 % - 48.17 %
Short MA 12 mos Sell Very High Jun 08, 2020 - 64 days
Long MA 12 mos Buy Very High May 01, 2020 - 89 days
Short/Long MA 12 mos Buy Very High May 05, 2020 - 87 days
Pivot Long Sell Low May 12, 2020 - 82 days
RSI Long Pivot Signal Buy Low Jul 07, 2020 - 44 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT STEMLINE THERAPEUTICS
Stemline Therapeutics
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States. It develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for advanced hematologic cancers; SL-701, an immunotherapy to attack tumors that is in Phase II clinical trial; and SL-80...
GOLDEN STAR
Ticker Change Signal Date
EAT
$140.46
7.38% Jun 05
TPR
$140.47
3.67% Jun 04
N
NVRI
$19.53
8.19% May 20
SAP
$172.39
3.79% May 05
GLBE
$31.61
2.44% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE